Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
about
Current Experimental Studies of Gene Therapy in Parkinson's DiseaseEEG machine learning for accurate detection of cholinergic intervention and Alzheimer's disease.Recent advances in treating Parkinson's disease.Parkinson's Disease: From Pathogenesis to PharmacogenomicsCell specificity dictates similarities in gene expression in multiple sclerosis, Parkinson's disease, and Alzheimer's disease.Neuroprotective Effects of Loganin on MPTP-Induced Parkinson's Disease Mice: Neurochemistry, Glial Reaction and Autophagy Studies.199 years of Parkinson disease - what have we learned and what is the path to the future?Alpha-synuclein and iron: two keys unlocking Parkinson's disease.Pathological overproduction: the bad side of adenosine.The use of nonhuman primate models to understand processes in Parkinson's disease.Non-human primate models of PD to test novel therapies.Mitochondrial dynamics in Parkinson's disease: a role for α-synuclein?MicroRNAs and Target Genes As Biomarkers for the Diagnosis of Early Onset of Parkinson Disease.The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.Mechanistic contributions of FBXO7 to Parkinson disease.Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.Vaccination strategies in tauopathies and synucleinopathies.Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings.Role of the microtubule-associated TPPP/p25 in Parkinson's and related diseases and its therapeutic potential.Neuroprotective effects of E-PodoFavalin-15999 (Atremorine®).ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'.C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction.The Neuroprotective Effects of Cinnamic Aldehyde in an MPTP Mouse Model of Parkinson's Disease.Neural circuits of eating behaviour: Opportunities for therapeutic development.[Pharmacological treatment of motor symptoms in Parkinson's diseases].Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.Perceived Treatment Status of Fluctuations in Parkinson Disease Impacts Suicidality.A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.Adipose-derived Stem Cells Stimulated with n-Butylidenephthalide Exhibit Therapeutic Effects in a Mouse Model of Parkinson's Disease.The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's ratsThe Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's DiseaseDeep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's DiseaseCell-type-specific interrogation of CeA Drd2 neurons to identify targets for pharmacological modulation of fear extinction
P2860
Q33627771-DC7B456D-16F8-4546-84D1-EEA00E7436CEQ33915806-6D35CBAB-5392-4F18-BC4D-B2916A7121C5Q34554401-871EB88D-660A-48EF-BBAE-B0A9CD9D3F86Q37729129-B952ED7A-AEB6-4FBC-A475-F2B70E2053DBQ38675620-DCC34A9F-3499-4248-BD50-F73160F53DA4Q38740508-1EAE64EB-80DA-4193-ADD1-1D048478024AQ38825770-93F19BF7-2D9B-4669-AD37-43B9B3A1C53CQ39123736-8B664190-5ED7-4880-9E46-22B76DC04255Q39157893-9C03638F-9ED8-44E0-A8C6-6ACE923D8A09Q39208290-FAD88A11-9ACD-4074-8EFF-28DC99DD246EQ39229450-8ECF3EB1-0A86-4930-B546-73DFA4AE5B28Q41664833-23E6E96E-AB8B-4169-A521-89E1C86FAAD7Q47102033-8EA8B7DB-66C2-4B01-8E34-2CDF1BFC3B72Q47332706-55E223BE-D25E-4F8B-8051-37926C885945Q47406006-972D3E31-5030-441F-8CE0-41447EE649E5Q47722876-3225F4FD-26DE-49C0-9B2E-9DF891CBC264Q47860105-0649E0ED-2065-4082-902F-138BDD05CA9FQ48129166-C458CD81-76AD-4930-B5AA-E0E100FC058FQ48191413-B82C32E0-EC77-4A71-82B4-D33E030E5B51Q48274208-593AE866-4A0D-4162-8A5D-D91574DB55FAQ48329113-0DE81C03-F4B0-4C2F-A9BA-AF5662814DBFQ48370307-86F1DBC3-E5CC-4F8F-9946-3BC2878F0149Q49829897-98CC7FE0-9035-4CA0-8B23-C267E8E1B3F6Q50033853-ECCDCDB8-BFEC-41BD-9C8A-506B057110D2Q50046451-BAC18C45-3D85-4C1F-AFE5-8E5C3ED8E028Q52703430-1931F5DC-3D51-43A8-A153-2F15679631E0Q52734704-DAE6C7F2-FE0A-4502-81DB-1D22BFFE88C6Q53419907-A113CD8F-DC4C-41BF-8F92-06F59D677A85Q53684476-7DB140F0-0426-43AC-A562-75A7A854E0D2Q55667027-3D824112-5BAF-48B5-BB84-D93EA9A61C10Q57177116-DADC4B6E-D5AD-47F1-9F2B-14B84F8AE461Q57896320-7CF2D60B-3CC3-4A21-B0FE-6BE6D6ACCFC9Q58700802-E752DC13-4E63-45F4-A8C8-5A228D0BD42DQ58721696-21B4F722-D8A6-40D1-B844-6F390C05BB79
P2860
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
@en
type
label
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
@en
prefLabel
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
@en
P2860
P356
P1476
Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
@en
P2860
P304
P356
10.1111/JNC.13750
P407
P478
139 Suppl 1
P577
2016-08-30T00:00:00Z